<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136046">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01746680</url>
  </required_header>
  <id_info>
    <org_study_id>m308RAP11M</org_study_id>
    <nct_id>NCT01746680</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis</brief_title>
  <acronym>TIARA</acronym>
  <official_title>Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to assess the efficacy and safety of tacrolimus in patients with
      active rheumatoid arthritis(RA). EULAR response at week 24 compared to baseline will be
      evaluated to assess the efficacy of Tacrolimus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase IV, Open labeled, Multi-Center Trial to Assess the Efficacy and Safety of
      Tacrolimus(Tacrobell®)in patients with active rheumatoid arthritis(RA).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tacrolimus with Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have tacrolimus per oral once daily with methotrexate for week 24. tacrolimus increased dosing regimen: 1 mg for 0~week4, 2mg for week4~week8,3mg for week8~week24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus with Methotrexate</intervention_name>
    <description>TacroBell1® 1 mg for 0~week4, 2mg for week4~week8,3mg for week8~week24 with MTX ≤20mg/week</description>
    <arm_group_label>Tacrolimus with Methotrexate</arm_group_label>
    <other_name>TacroBell® with MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged ≥20years

          -  Signed and dated informed consent document indicating that the patient

          -  Women of childbearing potential must have a negative serum or urine pregnancy test at
             the screening visit. Except in the case of surgically sterile or amenorrhea for one
             year.

          -  Female patients must agree to use adequate contraception measures during the period
             of therapy which should be continued for 4 weeks.

          -  have RA and meet all of the following criteria; RA occurring ≥ 3months and less than
             15 years and diagnosed based on 1987 ACR classification criteria for rheumatoid
             arthritis; Active RA patients with MTX and among them who has insufficiency response
             to DMARDs as defined DAS28&gt;3.2 in active RA patient. Insufficiency response is
             defined despite MTX therapy for &gt; 12 weeks, RA activity≥ more than moderate and
             confirmable during 12 weeks, sequence of taking MTX &gt;7.5mg/week for more than 6
             weeks; ESR≥28mm/h or CRP≥1.0mg/dl; Tender Joint Counts must be more than 6 and
             Swollen Joint Counts must be more than 3

        Exclusion Criteria:

          -  inflammatory joint diseases,systematic inflammatory disease

          -  prosthesis and had an event of infected in it.

          -  medical history of chronic infection, moderate infection or possibly to  life
             threatening or signs and symptoms of serious infection

          -  HBsAg positive and anti-HCV positive patient

          -  uncontrollable blood sugar(HbA1C ≥8%) or required insulin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung -Jae Hong, phD, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Kyung-Hee University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung Jae Hong, Ph.D</last_name>
    <phone>82-2-968-8199</phone>
    <email>hsj718@khu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Jae Hong, Ph.D</last_name>
      <phone>82-2-958-8199</phone>
      <email>hsj718@khu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seung -Jae Hong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 9, 2012</lastchanged_date>
  <firstreceived_date>December 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>DAS28</keyword>
  <keyword>EULAR</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
